Rhabdomyosarcoma: the Stanford experience using a TNM staging system

Area of Science:

• Pediatric Oncology
• Cancer Staging
• Clinical Trials

Background:

• Rhabdomyosarcoma staging traditionally used the Intergroup Rhabdomyosarcoma Study (IRS) grouping.
• A retrospective analysis evaluated the TNM staging system for rhabdomyosarcoma based on initial clinical disease extent.

Purpose of the Study:

• To compare the efficacy of the TNM staging system versus the IRS system for rhabdomyosarcoma.
• To identify significant prognostic factors for relapse and survival in rhabdomyosarcoma patients.

Main Methods:

• Retrospective analysis of 74 rhabdomyosarcoma patients staged using both IRS and TNM systems.
• TNM system components: T (tumor extent), N (lymph node involvement), M (metastasis).
• Multivariate analysis to assess impact of histologic subtype, primary site, T stage, and M stage on outcomes.

Main Results:

• The TNM system provided a more uniform distribution of patients compared to the IRS system.
• 10-year freedom from relapse (FFR) was 43% and survival was 47% for the entire cohort.
• TNM stage I patients had excellent outcomes; FFR and survival decreased with increasing TNM stage (II-IV).
• T stage was the most significant predictor of survival; a T and M stage model best predicted relapse.
• Lymph node involvement (N1) was associated with T2 primary lesions.

Conclusions:

• The TNM staging system demonstrates superior uniformity and prognostic value for rhabdomyosarcoma compared to the IRS system.
• T stage and M stage are critical prognostic indicators for rhabdomyosarcoma.
• Prospective use of the TNM staging system is recommended for future rhabdomyosarcoma therapeutic trials.